Show simple item record

dc.contributor.authorMachiels, J-P
dc.contributor.authorTao, Y
dc.contributor.authorBurtness, B
dc.contributor.authorTahara, M
dc.contributor.authorLicitra, L
dc.contributor.authorRischin, D
dc.contributor.authorWaldron, J
dc.contributor.authorSimon, C
dc.contributor.authorGregoire, V
dc.contributor.authorHarrington, K
dc.contributor.authorAlves, GV
dc.contributor.authorLima, IPF
dc.contributor.authorPointreau, Y
dc.contributor.authorHughes, BGM
dc.contributor.authorAksoy, S
dc.contributor.authorHetnal, M
dc.contributor.authorGe, JY
dc.contributor.authorBrown, H
dc.contributor.authorCheng, J
dc.contributor.authorBidadi, B
dc.contributor.authorSiu, LL
dc.date.accessioned2020-11-27T00:20:26Z
dc.date.available2020-11-27T00:20:26Z
dc.date.issued2020-06-03
dc.identifier.citationMachiels, J. -P., Tao, Y., Burtness, B., Tahara, M., Licitra, L., Rischin, D., Waldron, J., Simon, C., Gregoire, V., Harrington, K., Alves, G. V., Lima, I. P. F., Pointreau, Y., Hughes, B. G. M., Aksoy, S., Hetnal, M., Ge, J. Y., Brown, H., Cheng, J. ,... Siu, L. L. (2020). Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412. FUTURE ONCOLOGY, 16 (18), pp.1235-1243. https://doi.org/10.2217/fon-2020-0184.
dc.identifier.issn1479-6694
dc.identifier.urihttp://hdl.handle.net/11343/252429
dc.description.abstractCurrent treatment guidelines for patients with locally advanced head and neck squamous cell carcinoma (HNSCC) recommend multimodal treatment, including chemoradiation therapy (CRT) or surgery followed by radiation, with or without chemotherapy. The immune checkpoint inhibitor pembrolizumab has previously demonstrated antitumor activity in recurrent and/or metastatic HNSCC in large Phase III trials. For patients with locally advanced disease, Phase Ib data on the use of pembrolizumab in combination with chemoradiation have shown the approach to be safe and feasible. We describe here the design and rationale for KEYNOTE-412, a randomized, double-blind, Phase III trial investigating pembrolizumab or placebo administered concurrently with CRT and as maintenance treatment in patients with locally advanced HNSCC.
dc.languageEnglish
dc.publisherFUTURE MEDICINE LTD
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0
dc.titlePembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412
dc.typeJournal Article
dc.identifier.doi10.2217/fon-2020-0184
melbourne.affiliation.departmentMedicine and Radiology
melbourne.source.titleFuture Oncology
melbourne.source.volume16
melbourne.source.issue18
melbourne.source.pages1235-1243
dc.rights.licensecc-by-nc-nd
melbourne.elementsid1451619
melbourne.contributor.authorRischin, Danny
dc.identifier.eissn1744-8301
melbourne.accessrightsOpen Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record